Document is current
Any future updates will be listed below
-
Authors
Elomaa, Hanna
Tarkiainen, Vilma
Äijälä, Ville K.
Sirniö, Päivi
Ahtiainen, Maarit
Sirkiä, Onni
Karjalainen, Henna
Kastinen, Meeri
Tapiainen, Vilja V.
Rintala, Jukka
Meriläinen, Sanna
Saarnio, Juha
Rautio, Tero
Tuomisto, Anne https://orcid.org/0000-0002-9949-1887
Helminen, Olli
Wirta, Erkki-Ville
Seppälä, Toni T.
Böhm, Jan
Mäkinen, Markus J. https://orcid.org/0000-0002-9200-4118
Mecklin, Jukka-Pekka
Väyrynen, Juha P. https://orcid.org/0000-0002-8683-2996
-
Funding
Funding for this research was provided by:
Syöpäsäätiö (59-5619, 64-6279)
Emil Aaltosen Säätiö (220257P, 220022K)
Sigrid Juséliuksen Säätiö (230229)
Finnish State Research Funding
- License Information
-
More Information
Article History
Received: 4 August 2024
Revised: 21 January 2025
Accepted: 10 February 2025
First Online: 18 February 2025
Competing interests
: TT Seppälä reports consultation fees from Mehiläinen, Tillots Pharma and Nouscom, being a co-owner and CEO of Healthfund Finland Ltd, and a position in the Clinical Advisory Board and as a minor shareholder of Lynsight Ltd. The remaining authors declare no competing interests.
: The study was conducted according to the guidelines of the Declaration of Helsinki. The main cohort was approved by the Regional Medical Research Ethics Committee of the Wellbeing services county of Central Finland (Dnro13U/2011, 1/2016, 8/2020, and 2/2023), the Finnish Medicines Agency (Fimea), and the Central Finland Biobank (BB23-0172). The need to obtain informed consent from the study patients was waived (Dnro FIMEA/2023/001573, 4/2023). The validation cohort was approved by the Regional medical research ethics committee of the Wellbeing services county of North Ostrobothnia (25/2002, 42/2005, 122/2009, 37/2020), Fimea (FIMEA/2022/001941), and Biobank Borealis (BB-2017_1012). Patients gave written informed consent for the study.
